Zacks Investment Research on MSN5h
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key InsightsThe most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...
BofA notes press reports that the Trump administration is allegedly considering cutting HIV prevention activities from the CDC budget and that ...
We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other ...
The S&P 500 added 1.1% on Wednesday, March 19, 2025, as the Fed held interest rates steady, reaffirming plans for future cuts ...
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
With cancer diagnoses and death rates in Michigan often higher than the national average, a new, patient-centered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback